The Severe Asthma market report also offers comprehensive insights into the Severe Asthma market size, share, Severe Asthma epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Severe Asthma market size growth forward.
Some of the key highlights from the Severe Asthma Market Insights Report:
In September 2024, Kinaset Therapeutics announced two oral presentations and a late-breaking poster presentation at the 2024 European Respiratory Society (ERS) Congress. These presentations highlight the potential of frevecitinib (KN-002), the company’s lead clinical candidate, for treating moderate to severe asthma and COPD patients.
In May 2024, GSK reported positive topline results from its SWIFT-1 and SWIFT-2 Phase III trials, which evaluated the efficacy and safety of depemokimab compared to a placebo in adults and adolescents with severe asthma associated with type 2 inflammation and elevated blood eosinophil counts.
In April 2024, Sanofi announced that 25 abstracts covering both approved and investigational treatments would be presented at the American Thoracic Society (ATS) International Conference. A key highlight includes the first Phase IIb data presentation on rilzabrutinib for moderate to severe asthma.
Several key pharmaceutical companies, including AstraZeneca plc, GlaxoSmithKline plc, Sanofi S.A., Novartis AG, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals, Inc., Johnson & Johnson, Pfizer Inc., Bristol Myers Squibb, Eli Lilly and Company, Vertex Pharmaceuticals Incorporated, Amgen Inc., AbbVie Inc., Genentech, Inc., Gilead Sciences, Inc., Biogen Inc., CSL Limited, and others, are developing novel products to improve the Severe Asthma treatment outlook.
Severe asthma therapies are Cinqair (reslizumab), Fasenra (benralizumab), GSK3511294 (Depemokimab), PT010, and others.
The expansion of the severe asthma market is anticipated to be primarily driven by the increasing prevalence of the condition, advancements in diagnostic techniques, a surge in product launches, and growing pharmaceutical research efforts.
Asthma cases diagnosed by severity are categorized into two main groups: Intermittent and Persistent, with the latter further classified into mild, moderate, and severe forms. In 2023, intermittent asthma represented the highest number of cases, totaling approximately 25 million across the 7MM (Seven Major Markets).
Within the 7MM, the United States recorded the highest number of severe asthma cases, reaching around 2 million in 2023, followed by Japan with approximately 0.8 million cases.
Among the currently approved biologics for severe asthma treatment, Dupixent (dupilumab) is projected to achieve the largest market share by 2034 in the 7MM.
With the anticipated approval of new therapies between 2024 and 2034, the severe asthma treatment market is expected to witness significant growth, with a robust compound annual growth rate (CAGR) over the forecast period.
As per DelveInsight analysis, the Severe Asthma market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Severe Asthma Market Landscape
Severe Asthma Overview
Severe asthma is a significant challenge among respiratory diseases, marked by persistent and debilitating symptoms that persist despite standard treatments. Unlike milder forms, it often involves ongoing symptoms that greatly impact daily life and overall well-being. This complexity arises from multiple factors, including airway inflammation, structural changes (remodeling), and heightened responsiveness, leading to recurrent bronchial obstruction and airflow restriction. Additionally, the classification of severe asthma into type-2 and non-type-2 inflammation highlights its diverse nature, requiring personalized treatment strategies. While advancements in asthma management have been made, many individuals with severe asthma still struggle to achieve adequate control, emphasizing the critical need for targeted therapies to address this unmet medical challenge.
Do you know the treatment paradigms for different countries? Download our Severe Asthma Market Sample Report
Severe Asthma Epidemiology Insights
In 2023, approximately 26 million diagnosed cases of asthma were reported in the United States, encompassing both pediatric and adult populations.
Across the 7MM, the total number of diagnosed severe asthma cases reached 5.1 million, accounting for about 9% of all diagnosed asthma cases. Forecasts suggest a significant rise in these numbers by 2034.
Severe Asthma Epidemiology Segmentation
DelveInsight’s Severe Asthma market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Severe Asthma historical patient pools and forecasted Severe Asthma patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Severe Asthma Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:
Severe Asthma Prevalence
Age-Specific Severe Asthma Prevalence
Gender-Specific Severe Asthma Prevalence
Diagnosed and Treatable Cases of Severe Asthma
Visit for more @ Severe Asthma Epidemiological Insights
Severe Asthma Treatment Market
Severe asthma is characterized not only by difficult-to-control symptoms but also by significant abnormalities in pulmonary function. Accurate diagnosis is challenging due to the lack of precise physiological characterization, often relying on symptom assessment and treatment response.
Diagnosis typically involves confirming episodic airflow obstruction or airway hyperresponsiveness and assessing reversibility through spirometry. A key indicator is an increase in FEV1 (forced expiratory volume in one second) by >200 mL and 12% after inhaling a short-acting beta-agonist (SABA).
Treatment primarily focuses on reducing airway inflammation and preventing symptoms. Inhaled corticosteroids (ICS) are the cornerstone for persistent asthma, while SABAs provide quick relief during acute symptoms. If asthma remains uncontrolled, additional long-term controller medications such as long-acting beta-agonists (LABAs), montelukast, or theophylline may be introduced. Oral corticosteroids are considered for patients with persistent symptoms and flare-ups.
For severe cases, six approved monoclonal antibodies (omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab) serve as biologic add-on therapies. However, no approved treatments currently exist for severe non-eosinophilic asthma, which does not respond to corticosteroids.
Severe Asthma Market Outlook
The Severe Asthma market is evolving with a focus on reducing symptoms, minimizing side effects, and maintaining normal activity levels. Management strategies prioritize disease severity and the selection of appropriate therapies to control symptoms and prevent exacerbations.
For mild persistent asthma, low-dose inhaled corticosteroids (ICS) effectively reduce severe attacks and improve control. If symptoms persist, combining ICS with long-acting beta-agonists (LABA) is the preferred approach, along with short-acting beta-agonists (SABA) as needed. An alternative strategy involves using ICS/LABA as both maintenance and reliever therapy.
In severe cases, higher doses of inhalers and additional medications like anticholinergics help relax airway muscles. However, long-term reliance on combination inhaled therapies may be insufficient, and oral steroids pose risks due to potential side effects.
The market is experiencing growth with the development of novel therapies. Leading pharmaceutical companies, including GlaxoSmithKline, AstraZeneca, Bond Avillion, Novartis, Roche, AB Science, and Theravance Biopharma, are actively investing in research and innovation to address unmet medical needs and enhance treatment outcomes for severe asthma patients.
Severe Asthma Marketed Therapies
Cinqair (reslizumab): Teva Pharmaceutical
Fasenra (benralizumab): AstraZeneca
Severe Asthma Emerging Therapies
GSK3511294 (Depemokimab): GlaxoSmithKline
PT010: AstraZeneca
Severe Asthma Key Companies
AstraZeneca plc, GlaxoSmithKline plc, Sanofi S.A., Novartis AG, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals, Inc., Johnson & Johnson, Pfizer Inc., Bristol Myers Squibb, Eli Lilly and Company, Vertex Pharmaceuticals Incorporated, Amgen Inc., AbbVie Inc., Genentech, Inc., Gilead Sciences, Inc., Biogen Inc., CSL Limited, and others
For more information, visit Severe Asthma Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Severe Asthma Market Report:
11 Years Forecast
7MM Coverage
Descriptive overview of Severe Asthma, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Severe Asthma epidemiology in the 7MM
Severe Asthma marketed and emerging therapies
Severe Asthma companies
Severe Asthma market drivers and barriers
Table of Contents:
1 Severe Asthma Market Key Comprehensive Insights
2 Severe Asthma Market Report Introduction
3 Competitive Intelligence Analysis for Severe Asthma
4 Severe Asthma Market Analysis Overview at a Glance
5 Executive Summary of Severe Asthma
6 Severe Asthma Epidemiology and Market Methodology
7 Severe Asthma Epidemiology and Patient Population
8 Severe Asthma Patient Journey
9 Severe Asthma Treatment Algorithm, Severe Asthma Current Treatment, and Medical Practices
10 Key Endpoints in Severe Asthma Clinical Trials
11 Severe Asthma Marketed Therapies
12 Severe Asthma Emerging Therapies
13 Severe Asthma: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Severe Asthma
16 Severe Asthma Market Key Opinion Leaders Reviews
18 Severe Asthma Market Drivers
19 Severe Asthma Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Severe Asthma Epidemiology 2034
DelveInsight’s “Severe Asthma – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Severe Asthma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Severe Asthma Pipeline 2024
“Severe Asthma Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Severe Asthma market. A detailed picture of the Severe Asthma pipeline landscape is provided, which includes the disease overview and Severe Asthma treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
